α-methylacyl-CoA racemase: A new molecular marker for prostate cancer

Identification of genes that are dysregulated in association with prostate carcinogenesis can provide disease markers and clues relevant to disease etiology. Of particular interest as candidate markers of disease are those genes that are frequently overexpressed. In this study, we describe a gene, α-methylacyl-CoA racemase (AMACR), whose expression is consistently up-regulated in prostate cancer. Analysis of mRNA levels of AMACR revealed an average up-regulation of ∼9 fold in clinical prostate cancer specimens compared with normal. Western blot and immunohistochemical analysis confirms the up-regulation at the protein level and localizes the enzyme predominantly to the peroxisomal compartment of prostate cancer cells. A detailed immunohistochemical analysis of samples from 168 primary prostate cancer cases using both standard slides and tissue microarrays demonstrates that both prostate carcinomas and the presumed precursor lesion (high-grade prostatic intraepithelial neoplasia) consistently scored significantly higher than matched normal prostate epithelium; 88% of the carcinomas had a staining score higher than the highest score observed for any sample of normal prostate epithelium. Both untreated metastases (n = 32 patients) and hormone refractory prostate cancers (n = 14 patients) were generally strongly positive for AMACR. To extend the utility of this marker for prostate cancer diagnosis, we combined staining for cytoplasmic AMACR with staining for the nuclear protein, p63, a basal cell marker in the prostate that is absent in prostate cancer. In a simple assay that can be useful for the diagnosis of prostate cancer on both biopsy and surgical specimens, combined staining for p63 and AMACR resulted in a staining pattern that greatly facilitated the identification of malignant prostate cells. The enzyme encoded by the AMACR gene plays a critical role in peroxisomal β oxidation of branched chain fatty acid molecules. These observations could have important epidemiological and preventive implications for prostate cancer, as the main sources of branched chain fatty acids are dairy products and beef, the consumption of which has been associated with an increased risk for prostate cancer in multiple studies. On the basis of its consistency and magnitude of cancer cell-specific expression, we propose AMACR as an important new marker of prostate cancer and that its use in combination with p63 staining will form the basis for an improved staining method for the identification of prostate carcinomas. Furthermore, the absence of AMACR staining in the vast majority of normal tissues coupled with its enzymatic activity makes AMACR the ideal candidate for development of molecular probes for the noninvasive identification of prostate cancer by imaging modalities.

[1]  A. Ferretti,et al.  Characterization of two steroidal ketones and two isoprenoid alcohols in dairy products. , 1975, Journal of lipid research.

[2]  T. Stamey,et al.  Microcarcinoma in the prostate: its association with duct-acinar dysplasia. , 1991, Human pathology.

[3]  N M Bass,et al.  Fatty‐acid metabolism and the pathogenesis of hepatocellular carcinoma: Review and hypothesis , 1993, Hepatology.

[4]  J. Epstein,et al.  Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[5]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Epstein,et al.  The Utility of Basal Cell—Specific Anti‐Cytokeratin Antibody (34βE12) in the Diagnosis of Prostate Cancer: A Review of 228 Cases , 1995, The American journal of surgical pathology.

[7]  K. Kinzler,et al.  The Genetic Basis of Human Cancer , 1997 .

[8]  R. Nagle,et al.  Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma. , 1997, The American journal of pathology.

[9]  J. Epstein,et al.  E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. , 1999, Urology.

[10]  K. Hattori,et al.  Neoplastic conversion of human urothelial cells in vitro by overexpression of H2O2-generating peroxisomal fatty acyl CoA oxidase. , 1999, International journal of oncology.

[11]  S. Reed,et al.  Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. , 2000, Cancer research.

[12]  S. Ferdinandusse,et al.  Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. , 2000, Journal of lipid research.

[13]  R Montironi,et al.  p63 is a prostate basal cell marker and is required for prostate development. , 2000, The American journal of pathology.

[14]  J. Reddy,et al.  Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. , 2000, Mutation research.

[15]  Scott E. Fraser,et al.  In vivo visualization of gene expression using magnetic resonance imaging , 2000, Nature Biotechnology.

[16]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[17]  M. Stampfer,et al.  Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. , 2001, The American journal of clinical nutrition.

[18]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[19]  M. Rubin,et al.  Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. , 2001, The American journal of pathology.

[20]  Gerbert A. Jansen,et al.  Peroxisomal fatty acid α- and β-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases , 2001 .

[21]  M. Bittner,et al.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.

[22]  W. Isaacs,et al.  Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. , 2001, Cancer Research.

[23]  G. Muir,et al.  Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray , 2001, British Journal of Cancer.

[24]  W. Gage,et al.  p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. , 2001, Urology.

[25]  S. Reed,et al.  P504S: A New Molecular Marker for the Detection of Prostate Carcinoma , 2001, The American journal of surgical pathology.

[26]  J. Epstein,et al.  The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. , 2001, The Journal of urology.

[27]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.